Bloom Science to Participate at Upcoming Patient Advocacy Conferences

SAN DIEGO, Calif., June 20, 2024 — Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that the company will participate in two upcoming patient advocacy conferences.

2024 Dravet Syndrome Foundation Conference in Minneapolis
Date: June 20-22, 2024
Location: Minneapolis

ALS Nexus 2024
Date: July 14 – 17, 2024
Location: Dallas

Poster Presentation: Development of BL-001 for the Treatment of ALS through Multiple Gut-Brain Mediated Pathways. PResenter: Christopher Reyes, PhD

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.